Adenosine

Endogenous adenosine receptor agonist CAS# 58-61-7

Adenosine

Catalog No. BCN5796----Order now to get a substantial discount!

Product Name & Size Price Stock
Adenosine: 5mg $12 In Stock
Adenosine: 10mg Please Inquire In Stock
Adenosine: 20mg Please Inquire Please Inquire
Adenosine: 50mg Please Inquire Please Inquire
Adenosine: 100mg Please Inquire Please Inquire
Adenosine: 200mg Please Inquire Please Inquire
Adenosine: 500mg Please Inquire Please Inquire
Adenosine: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Adenosine

Number of papers citing our products

Chemical structure

Adenosine

3D structure

Chemical Properties of Adenosine

Cas No. 58-61-7 SDF Download SDF
PubChem ID 60961 Appearance White powder
Formula C10H13N5O4 M.Wt 267.2
Type of Compound Alkaloids Storage Desiccate at -20°C
Synonyms Adenine riboside; D-Adenosine;Adenoscan;Adenine riboside
Solubility DMSO : 33.33 mg/mL (124.72 mM; Need ultrasonic)
H2O : ≥ 6.67 mg/mL (24.96 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
SMILES C1=NC2=C(C(=N1)N)N=CN2C3C(C(C(O3)CO)O)O
Standard InChIKey OIRDTQYFTABQOQ-KQYNXXCUSA-N
Standard InChI InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7-,10-/m1/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of Adenosine

The rhizome of Typhonium giganteum Engl.

Biological Activity of Adenosine

DescriptionAdenosine is a nucleoside composed of a molecule of adenine attached to a ribose sugar molecule (ribofuranose) moiety via a β-N9-glycosidic bond. Adenosine induces SphK1 activity in human and mouse sickle and normal erythrocytes in vitro, it can activate the neuroimmune system, alter neuronal function and neurotransmission,and contribute to symptoms of sickness and psychopathologies. Adenosine activates mast cells have been long implicated in allergic asthma and studies in rodent mast cells have assigned the A3 Adenosine receptor (A3R) a primary role in mediating Adenosine responses.
TargetsERK | IL Receptor | VEGFR | cAMP | A3 Adenosine receptor | SphK1
In vitro

Down-regulation of the A3 adenosine receptor in human mast cells upregulates mediators of angiogenesis and remodeling.[Pubmed: 25597247]

Mol Immunol. 2015 May;65(1):25-33.

Adenosine activated mast cells have been long implicated in allergic asthma and studies in rodent mast cells have assigned the A3 Adenosine receptor (A3R) a primary role in mediating Adenosine responses.
METHODS AND RESULTS:
Here we analyzed the functional impact of A3R activation on genes that are implicated in tissue remodeling in severe asthma in the human mast cell line HMC-1 that shares similarities with lung derived human mast cells. Quantitative real time PCR demonstrated upregulation of IL6, IL8, VEGF, amphiregulin and osteopontin. Moreover, further upregulation of these genes was noted upon the addition of dexamethasone. Unexpectedly, activated A3R down regulated its own expression and knockdown of the receptor replicated the pattern of agonist induced gene upregulation.
CONCLUSIONS:
This study therefore identifies the human mast cell A3R as regulator of tissue remodeling gene expression in human mast cells and demonstrates a heretofore-unrecognized mode of feedback regulation that is exerted by this receptor.

In vivo

Adenosine transiently modulates stimulated dopamine release in the caudate-putamen via A1 receptors.[Pubmed: 25219576]

J Neurochem. 2015 Jan;132(1):51-60.

Adenosine modulates dopamine in the brain via A1 and A2A receptors, but that modulation has only been characterized on a slow time scale. Recent studies have characterized a rapid signaling mode of Adenosine that suggests a possible rapid modulatory role.
METHODS AND RESULTS:
Here, fast-scan cyclic voltammetry was used to characterize the extent to which transient Adenosine changes modulate stimulated dopamine release (5 pulses at 60 Hz) in rat caudate-putamen brain slices. Exogenous Adenosine was applied and dopamine concentration monitored. Adenosine only modulated dopamine when it was applied 2 or 5 s before stimulation. Longer time intervals and bath application of 5 μM Adenosine did not decrease dopamine release. Mechanical stimulation of endogenous Adenosine 2 s before dopamine stimulation also decreased stimulated dopamine release by 41 ± 7%, similar to the 54 ± 6% decrease in dopamine after exogenous Adenosine application. Dopamine inhibition by transient Adenosine was recovered within 10 min. The A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine blocked the dopamine modulation, whereas dopamine modulation was unaffected by the A2A receptor antagonist SCH 442416. Thus, transient Adenosine changes can transiently modulate phasic dopamine release via A1 receptors. These data demonstrate that Adenosine has a rapid, but transient, modulatory role in the brain. Here, transient Adenosine was shown to modulate phasic dopamine release on the order of seconds by acting at the A1 receptor. However, sustained increases in Adenosine did not regulate phasic dopamine release.
CONCLUSIONS:
This study demonstrates for the first time a transient, neuromodulatory function of rapid Adenosine to regulate rapid neurotransmitter release.

Elevated adenosine signaling via adenosine A2B receptor induces normal and sickle erythrocyte sphingosine kinase 1 activity.[Pubmed: 25587035]

Blood. 2015 Mar 5;125(10):1643-52.

Erythrocyte possesses high sphingosine kinase 1 (SphK1) activity and is the major cell type supplying plasma sphingosine-1-phosphate, a signaling lipid regulating multiple physiological and pathological functions. Recent studies revealed that erythrocyte SphK1 activity is upregulated in sickle cell disease (SCD) and contributes to sickling and disease progression. However, how erythrocyte SphK1 activity is regulated remains unknown.
METHODS AND RESULTS:
Here we report that Adenosine induces SphK1 activity in human and mouse sickle and normal erythrocytes in vitro. Next, using 4 Adenosine receptor-deficient mice and pharmacological approaches, we determined that the A2B Adenosine receptor (ADORA2B) is essential for Adenosine-induced SphK1 activity in human and mouse normal and sickle erythrocytes in vitro. Subsequently, we provide in vivo genetic evidence that Adenosine deaminase (ADA) deficiency leads to excess plasma Adenosine and elevated erythrocyte SphK1 activity. Lowering Adenosine by ADA enzyme therapy or genetic deletion of ADORA2B significantly reduced excess Adenosine-induced erythrocyte SphK1 activity in ADA-deficient mice. Finally, we revealed that protein kinase A-mediated extracellular signal-regulated kinase 1/2 activation functioning downstream of ADORA2B underlies Adenosine-induced erythrocyte SphK1 activity.
CONCLUSIONS:
Overall, our findings reveal a novel signaling network regulating erythrocyte SphK1 and highlight innovative mechanisms regulating SphK1 activity in normal and SCD.

Modulation of neuroimmunity by adenosine and its receptors: metabolism to mental illness.[Pubmed: 25308443]

Metabolism. 2014 Dec;63(12):1491-8.

Adenosine is a pleiotropic bioactive with potent neuromodulatory properties. Due to its ability to easily cross the blood-brain barrier, it can act as a signaling molecule between the periphery and the brain. It functions through four (A1, A2A, A2B, and A3) cell surface G protein-coupled Adenosine receptors (ARs) that are expressed in some combination on nearly all cells types within the CNS. By regulating the activity of adenylyl cyclase and changing the intracellular concentration of cAMP, Adenosine can alter neuronal function and neurotransmission. A variety of illnesses related to metabolic dysregulation, such as type 1 diabetes and Alzheimer's disease, are associated with an elevated serum concentration of Adenosine and a pathogenesis rooted in inflammation.
CONCLUSIONS:
This review describes the accepted physiologic function of Adenosine in neurological disease and explores its new potential as a peripheral to central danger signal that can activate the neuroimmune system and contribute to symptoms of sickness and psychopathologies.

Protocol of Adenosine

Kinase Assay

Adenosine receptors: therapeutic aspects for inflammatory and immune diseases.[Reference: WebLink]

Nat. Rev. Drug Discov., 2008, 7(9):759-70.

Adenosine is a key endogenous molecule that regulates tissue function by activating four G-protein-coupled Adenosine receptors: A1, A2A, A2B and A3.
METHODS AND RESULTS:
Cells of the immune system express these receptors and are responsive to the modulatory effects of Adenosine in an inflammatory environment. Animal models of asthma, ischaemia, arthritis, sepsis, inflammatory bowel disease and wound healing have helped to elucidate the regulatory roles of the various Adenosine receptors in dictating the development and progression of disease.
CONCLUSIONS:
This recent heightened awareness of the role of Adenosine in the control of immune and inflammatory systems has generated excitement regarding the potential use of Adenosine-receptor-based therapies in the treatment of infection, autoimmunity, ischaemia and degenerative diseases.

Animal Research

Elevated placental adenosine signaling contributes to the pathogenesis of preeclampsia.[Pubmed: 25538227]

Circulation. 2015 Feb 24;131(8):730-41.

Preeclampsia is a prevalent hypertensive disorder of pregnancy and a leading cause of maternal and neonatal morbidity and mortality worldwide. This pathogenic condition is speculated to be caused by placental abnormalities that contribute to the maternal syndrome. However, the specific factors and signaling pathways that lead to impaired placentas and maternal disease development remain elusive.
CONCLUSIONS:
Using 2 independent animal models of preeclampsia (genetically engineered pregnant mice with elevated Adenosine exclusively in placentas and a pathogenic autoantibody-induced preeclampsia mouse model), we demonstrated that chronically elevated placental Adenosine was sufficient to induce hallmark features of preeclampsia, including hypertension, proteinuria, small fetuses, and impaired placental vasculature. Genetic and pharmacological approaches revealed that elevated placental Adenosine coupled with excessive A₂B Adenosine receptor (ADORA2B) signaling contributed to the development of these features of preeclampsia. Mechanistically, we provided both human and mouse evidence that elevated placental CD73 is a key enzyme causing increased placental Adenosine, thereby contributing to preeclampsia.
CONCLUSIONS:
We determined that elevated placental Adenosine signaling is a previously unrecognized pathogenic factor for preeclampsia. Moreover, our findings revealed the molecular basis underlying the elevation of placental Adenosine and the detrimental role of excess placental Adenosine in the pathophysiology of preeclampsia, and thereby, we highlight novel therapeutic targets.

Adenosine Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Adenosine Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Adenosine

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.7425 mL 18.7126 mL 37.4251 mL 74.8503 mL 93.5629 mL
5 mM 0.7485 mL 3.7425 mL 7.485 mL 14.9701 mL 18.7126 mL
10 mM 0.3743 mL 1.8713 mL 3.7425 mL 7.485 mL 9.3563 mL
50 mM 0.0749 mL 0.3743 mL 0.7485 mL 1.497 mL 1.8713 mL
100 mM 0.0374 mL 0.1871 mL 0.3743 mL 0.7485 mL 0.9356 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Adenosine

Adenosine is a nucleoside composed of a molecule of adenine attached to a ribose sugar molecule (ribofuranose) moiety via a β-N9-glycosidic bond.

Featured Products
New Products
 

References on Adenosine

Adenosine transiently modulates stimulated dopamine release in the caudate-putamen via A1 receptors.[Pubmed:25219576]

J Neurochem. 2015 Jan;132(1):51-60.

Adenosine modulates dopamine in the brain via A1 and A2A receptors, but that modulation has only been characterized on a slow time scale. Recent studies have characterized a rapid signaling mode of Adenosine that suggests a possible rapid modulatory role. Here, fast-scan cyclic voltammetry was used to characterize the extent to which transient Adenosine changes modulate stimulated dopamine release (5 pulses at 60 Hz) in rat caudate-putamen brain slices. Exogenous Adenosine was applied and dopamine concentration monitored. Adenosine only modulated dopamine when it was applied 2 or 5 s before stimulation. Longer time intervals and bath application of 5 muM Adenosine did not decrease dopamine release. Mechanical stimulation of endogenous Adenosine 2 s before dopamine stimulation also decreased stimulated dopamine release by 41 +/- 7%, similar to the 54 +/- 6% decrease in dopamine after exogenous Adenosine application. Dopamine inhibition by transient Adenosine was recovered within 10 min. The A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine blocked the dopamine modulation, whereas dopamine modulation was unaffected by the A2A receptor antagonist SCH 442416. Thus, transient Adenosine changes can transiently modulate phasic dopamine release via A1 receptors. These data demonstrate that Adenosine has a rapid, but transient, modulatory role in the brain. Here, transient Adenosine was shown to modulate phasic dopamine release on the order of seconds by acting at the A1 receptor. However, sustained increases in Adenosine did not regulate phasic dopamine release. This study demonstrates for the first time a transient, neuromodulatory function of rapid Adenosine to regulate rapid neurotransmitter release.

Elevated placental adenosine signaling contributes to the pathogenesis of preeclampsia.[Pubmed:25538227]

Circulation. 2015 Feb 24;131(8):730-41.

BACKGROUND: Preeclampsia is a prevalent hypertensive disorder of pregnancy and a leading cause of maternal and neonatal morbidity and mortality worldwide. This pathogenic condition is speculated to be caused by placental abnormalities that contribute to the maternal syndrome. However, the specific factors and signaling pathways that lead to impaired placentas and maternal disease development remain elusive. METHODS AND RESULTS: Using 2 independent animal models of preeclampsia (genetically engineered pregnant mice with elevated Adenosine exclusively in placentas and a pathogenic autoantibody-induced preeclampsia mouse model), we demonstrated that chronically elevated placental Adenosine was sufficient to induce hallmark features of preeclampsia, including hypertension, proteinuria, small fetuses, and impaired placental vasculature. Genetic and pharmacological approaches revealed that elevated placental Adenosine coupled with excessive A(2)B Adenosine receptor (ADORA2B) signaling contributed to the development of these features of preeclampsia. Mechanistically, we provided both human and mouse evidence that elevated placental CD73 is a key enzyme causing increased placental Adenosine, thereby contributing to preeclampsia. CONCLUSIONS: We determined that elevated placental Adenosine signaling is a previously unrecognized pathogenic factor for preeclampsia. Moreover, our findings revealed the molecular basis underlying the elevation of placental Adenosine and the detrimental role of excess placental Adenosine in the pathophysiology of preeclampsia, and thereby, we highlight novel therapeutic targets.

Down-regulation of the A3 adenosine receptor in human mast cells upregulates mediators of angiogenesis and remodeling.[Pubmed:25597247]

Mol Immunol. 2015 May;65(1):25-33.

Adenosine activated mast cells have been long implicated in allergic asthma and studies in rodent mast cells have assigned the A3 Adenosine receptor (A3R) a primary role in mediating Adenosine responses. Here we analyzed the functional impact of A3R activation on genes that are implicated in tissue remodeling in severe asthma in the human mast cell line HMC-1 that shares similarities with lung derived human mast cells. Quantitative real time PCR demonstrated upregulation of IL6, IL8, VEGF, amphiregulin and osteopontin. Moreover, further upregulation of these genes was noted upon the addition of dexamethasone. Unexpectedly, activated A3R down regulated its own expression and knockdown of the receptor replicated the pattern of agonist induced gene upregulation. This study therefore identifies the human mast cell A3R as regulator of tissue remodeling gene expression in human mast cells and demonstrates a heretofore-unrecognized mode of feedback regulation that is exerted by this receptor.

Elevated adenosine signaling via adenosine A2B receptor induces normal and sickle erythrocyte sphingosine kinase 1 activity.[Pubmed:25587035]

Blood. 2015 Mar 5;125(10):1643-52.

Erythrocyte possesses high sphingosine kinase 1 (SphK1) activity and is the major cell type supplying plasma sphingosine-1-phosphate, a signaling lipid regulating multiple physiological and pathological functions. Recent studies revealed that erythrocyte SphK1 activity is upregulated in sickle cell disease (SCD) and contributes to sickling and disease progression. However, how erythrocyte SphK1 activity is regulated remains unknown. Here we report that Adenosine induces SphK1 activity in human and mouse sickle and normal erythrocytes in vitro. Next, using 4 Adenosine receptor-deficient mice and pharmacological approaches, we determined that the A2B Adenosine receptor (ADORA2B) is essential for Adenosine-induced SphK1 activity in human and mouse normal and sickle erythrocytes in vitro. Subsequently, we provide in vivo genetic evidence that Adenosine deaminase (ADA) deficiency leads to excess plasma Adenosine and elevated erythrocyte SphK1 activity. Lowering Adenosine by ADA enzyme therapy or genetic deletion of ADORA2B significantly reduced excess Adenosine-induced erythrocyte SphK1 activity in ADA-deficient mice. Finally, we revealed that protein kinase A-mediated extracellular signal-regulated kinase 1/2 activation functioning downstream of ADORA2B underlies Adenosine-induced erythrocyte SphK1 activity. Overall, our findings reveal a novel signaling network regulating erythrocyte SphK1 and highlight innovative mechanisms regulating SphK1 activity in normal and SCD.

Modulation of neuroimmunity by adenosine and its receptors: metabolism to mental illness.[Pubmed:25308443]

Metabolism. 2014 Dec;63(12):1491-8.

Adenosine is a pleiotropic bioactive with potent neuromodulatory properties. Due to its ability to easily cross the blood-brain barrier, it can act as a signaling molecule between the periphery and the brain. It functions through four (A1, A2A, A2B, and A3) cell surface G protein-coupled Adenosine receptors (ARs) that are expressed in some combination on nearly all cells types within the CNS. By regulating the activity of adenylyl cyclase and changing the intracellular concentration of cAMP, Adenosine can alter neuronal function and neurotransmission. A variety of illnesses related to metabolic dysregulation, such as type 1 diabetes and Alzheimer's disease, are associated with an elevated serum concentration of Adenosine and a pathogenesis rooted in inflammation. This review describes the accepted physiologic function of Adenosine in neurological disease and explores its new potential as a peripheral to central danger signal that can activate the neuroimmune system and contribute to symptoms of sickness and psychopathologies.

Adenosine receptors as therapeutic targets.[Pubmed:16518376]

Nat Rev Drug Discov. 2006 Mar;5(3):247-64.

Adenosine receptors are major targets of caffeine, the most commonly consumed drug in the world. There is growing evidence that they could also be promising therapeutic targets in a wide range of conditions, including cerebral and cardiac ischaemic diseases, sleep disorders, immune and inflammatory disorders and cancer. After more than three decades of medicinal chemistry research, a considerable number of selective agonists and antagonists of Adenosine receptors have been discovered, and some have been clinically evaluated, although none has yet received regulatory approval. However, recent advances in the understanding of the roles of the various Adenosine receptor subtypes, and in the development of selective and potent ligands, as discussed in this review, have brought the goal of therapeutic application of Adenosine receptor modulators considerably closer.

Description

Adenosine is a nucleoside composed of a molecule of adenine attached to a ribose sugar molecule (ribofuranose) moiety via a β-N9-glycosidic bond.

Keywords:

Adenosine,58-61-7,Adenine riboside; D-Adenosine;Adenoscan;Adenine riboside,Natural Products,Nucleoside Antimetabolite/Analogue, buy Adenosine , Adenosine supplier , purchase Adenosine , Adenosine cost , Adenosine manufacturer , order Adenosine , high purity Adenosine

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: